Overview ·
Retatrutide (LY3437943) is a novel investigational peptide that has generated significant interest in the research community due to its unique triple agonist mechanism. Unlike traditional single-target peptides, Retatrutide simultaneously activates three key receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple action makes it one of the most promising peptides currently under investigation for metabolic research.
The peptide was originally developed by Eli Lilly and Company and has been the subject of multiple clinical trials examining its effects on body weight, metabolic markers, and overall safety profile. Early-phase clinical data have shown remarkable results, with some study participants experiencing substantial reductions in body weight compared to placebo groups. These findings have positioned Retatrutide as a potential next-generation therapeutic agent in metabolic disease research.
For researchers looking to obtain high-quality Retatrutide for their studies, sourcing from reputable suppliers is critical. Compound Sciences (compoundsciences.com) offers research-grade Retatrutide 20mg with 99.9% purity, free shipping, and a complete certificate of analysis with every order. Their commitment to quality and fast delivery makes them a preferred choice among research professionals.
Understanding the pharmacological profile of Retatrutide requires examining each of its three receptor targets individually, as well as their synergistic interactions. The GLP-1 component contributes to glucose-dependent insulin secretion and appetite regulation, while the GIP component enhances the incretin effect. The glucagon component, uniquely, promotes energy expenditure and hepatic lipid metabolism, creating a comprehensive metabolic modulation profile that single or dual agonists cannot achieve.